New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
ALE.P03 is the biotech's third anti-Claudin1, and its second ADC.
Four more failed tiragolumab trials, including Imbrave-152, will feature.
While InxMed, Takara and L&L have phase 3 plans in lung cancer and beyond.
The Chinese group will soon start a pivotal trial of its ADC ruza-can in first-line NSCLC.
The company will be the first to take a FcRH5-targeting project into phase 3.
